APOA1 antibody (AA 25-267) (DyLight 550)

Catalog No. ABIN7354543

This Rabbit Polyclonal antibody specifically detects APOA1 in FACS. It exhibits reactivity toward Human.

Quick Overview for APOA1 antibody (AA 25-267) (DyLight 550) (ABIN7354543)

Target: APOA1 (Apolipoprotein A-I (APOA1))

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This APOA1 antibody is conjugated to DyLight 550

Application: Flow Cytometry (FACS)

Product Details anti-APOA1 Antibody (DyLight 550)

Binding Specificity: AA 25-267

Purpose: Anti-Human Apolipoprotein A I DyLight® 550 conjugated APOA1 Antibody

Cross-Reactivity (Details): No cross-reactivity with other proteins.

Characteristics: Anti-Human Apolipoprotein A I DyLight® 550 conjugated APOA1 Antibody -Dyl550. Tested in Flow Cytometry applications. This antibody reacts with Human.

Purification: Immunogen affinity purified.

Immunogen: E. coli-derived human Apolipoprotein A I recombinant protein (Position: D25-Q267). Human Apolipoprotein A I shares 64% and 61.7% amino acid (aa) sequence identity with mouse and rat Apolipoprotein A I, respectively.

Isotype: IgG

Application Details

Application Notes: Flow Cytometry (Fixed), 1-3 μg/1x10⁶ cells1. Brewer, H. B., Jr., Fairwell, T., LaRue, A., Ronan, R., Houser, A., Bronzert, T. J. : The amino acid sequence of human apoA-I, an apolipoprotein isolated from high absorbance lipoproteins. Biochem. Biophys. Res. Commun. 80: 623-630, 1978. 2. Ma J, Liao XL, Lou B, Wu MP (2004). "Role of apolipoprotein A-I in protecting against endotoxin toxicity". Acta Biochim. Biophys. Sin. (Shanghai) 36 (6): 419-24. 3. Yui Y, Aoyama T, Morishita H, Takahashi M, Takatsu Y, Kawai C (1988). "Serum prostacyclin stabilizing factor is identical to apolipoprotein A-I (Apo A-I). A novel function of Apo A-I". J. Clin. Invest. 82 (3): 803-7. 4. Zhang, Y., Zanotti, I., Reilly, M. P., Glick, J. M., Rothblat, G. H., Rader, D. J. : Overexpression of apolipoprotein A-I promotes reverse transport of cholesterol from macrophages to feces in vivo. Circulation 108: 661-663, 2003.

Comment:

Other applications have not been tested. Optimal dilutions should be determined by end users.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: Lot specific

Buffer: Each vial contains 50 % glycerol, 0.9 % NaCl, 0.2 % Na2HPO4, 0.02 % Sodium azide.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: -20 °C

Storage Comment: At -20°C for one year from date of receipt. Avoid repeated freezing and thawing. Protect from light.

Target Details for APOA1

Target: APOA1 (Apolipoprotein A-I (APOA1))

Alternative Name: APOA1

Background:

Synonyms: Apolipoprotein A-I, Apo-AI, ApoA-I, Apolipoprotein A1, Proapolipoprotein A-I, ProapoA-I, Truncated apolipoprotein A-I, Apolipoprotein A-I (1-242), APOA1

Tissue Specificity: Major protein of plasma HDL, also found in chylomicrons. Synthesized in the liver and small intestine. The oxidized form at Met-110 and Met-136 is increased in individuals with increased risk for coronary artery disease, such as in carrier of the eNOSa/b genotype and exposure to cigarette smoking. It is also present in increased levels in aortic lesions relative to native ApoA-I and increased levels are seen with increasing severity of disease.

Background: Apolipoprotein A-1, also known as APOA1, is a human protein with a specific role in lipid metabolism. It binds to lipopolysaccharide or endotoxin, and has a major role in the anti-endotoxin function of HDL. The gene is mapped to 11q23. And it is a single polypeptide chain with 243 amino acid residues of known primary amino acid sequence. The ApoA-I protein promotes cholesterol efflux from tissues to the liver for excretion. It is a cofactor for lecithin cholesterolacyltransferase (LCAT) which is responsible for the formation of most plasma cholesteryl esters. ApoA-I is also isolated as a prostacyclin (PGI2) stabilizing factor, and thus may have an anticlotting effect. Defects in the gene encoding it are associated with HDL deficiencies, including Tangier disease, and with systemic non-neuropathic amyloidosis. Additionally, ApoA-I overexpression promotes macrophage-specific reverse cholesterol transport.

Molecular Weight: 39 kDa

Gene ID: 335

UniProt: P02647

Pathways: Regulation of Lipid Metabolism by PPARalpha, Production of Molecular Mediator of Immune Response, Lipid Metabolism